SonoVascular Initiates FIH Study for Ultrasound-Facilitated Thrombectomy System

August 27, 2024—SonoVascular, Inc. announced the start of a first-in-human (FIH) study for its SonoThrombectomy System.

The company describes the SonoVascular platform as an ultrasound-facilitated, thrombolytic-enhanced thrombectomy system that combines microbubble-mediated cavitation with low-dose thrombolytic delivery to treat patients with venous thromboembolism with no blood loss.

In this initial experience, deep vein thrombosis involving the common and external iliac veins was successfully treated by vascular surgeons Manuel Espíndola and Albrecht Krämer at Hospital DPIRECA in Santiago, Chile. Drs. Espíndola and Krämer are the FIH Site and Study Principal Investigators, respectively.

“We were extremely pleased to perform the first clinical case using the SonoThrombectomy System,” commented Dr. Espíndola in the company’s announcement. “The Resonator catheter performed exceptionally well, successfully and very quickly removing the thrombus and, most importantly, without the typical blood loss commonly seen in mechanical thrombectomy procedures. The patient was discharged from the hospital within 48 hours and is now at home, asymptomatic, and recovering well.”

“The SonoThrombectomy System was effective at reducing thrombus burden while preserving vessel walls due to its unique and gentle approach,” added Dr. Krämer. “It is exciting that we achieved such a comprehensive result on the table with a very low dose of thrombolytic.”